Today Myco Industries, Inc. (Myco), a privately held medical device company, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,404203 on September 3, 2019 for the AB Max™ – a new advanced doctor’s treatment for Anterior Blepharitis*.
John Choate, Chairman of Myco designed the AB Max™ to provide medical professionals with advanced functionality utilizing two onboard computers and proprietary tips specifically designed to treat Anterior Blepharitis*. As the U.S. Patent Office recognized, AB Max™ is a unique advancement over our competitor’s device since Myco’s patent covers the revolutionary pulse-mode feature of the AB Max™ after reviewing our competitors’ patent.
The AB Max™ offers the same forward and reverse functionality as our competitor, but also has a patented PULSE mode specifically engineered to remove even the most tenacious scurf and debris, while massaging the outer eyelid margins for better patient outcomes.